Introduction {#section1-jabfm.5000342}
============

Bone tissue engineering uses both life sciences and engineering knowledge to regenerate or improve the function of injured bone tissue via several approaches: osteogenic biomaterials ([@bibr1-jabfm.5000342]-[@bibr2-jabfm.5000342]-[@bibr3-jabfm.5000342]-[@bibr4-jabfm.5000342]), stem cells ([@bibr5-jabfm.5000342]-[@bibr6-jabfm.5000342]-[@bibr7-jabfm.5000342]-[@bibr8-jabfm.5000342]-[@bibr9-jabfm.5000342]) and supplementation with external specific growth factors and/or biophysical stimuli ([@bibr10-jabfm.5000342]-[@bibr11-jabfm.5000342]-[@bibr12-jabfm.5000342]-[@bibr13-jabfm.5000342]-[@bibr14-jabfm.5000342]). Many preclinical and clinical studies were focused on the evaluation of the efficacy of these approaches, alone or in combination. Scaffolds play a key role in bone tissue engineering providing a 3-dimensional environment and a highly interconnected porous structure for cell seeding, proliferation and growth, as well as for filling bone defects ([@bibr1-jabfm.5000342]). At the same time, they provide mechanical competence during bone regeneration. Biocompatibility, osteo-conductivity and/or inductivity, and suitable biodegradation rate are the properties required for a scaffold to be successful in bone tissue engineering. Scaffolds should also support attachment and proliferation of differentiating mesenchymal stem cells (MSCs) and osteoblasts ([@bibr15-jabfm.5000342]) and therefore enhance bone formation and angiogenesis. MSCs are the most common source of osteoprogenitor cells and they are often derived from bone marrow ([@bibr7-jabfm.5000342], [@bibr16-jabfm.5000342]), adipose tissue ([@bibr17-jabfm.5000342]), and other tissues such as periodontal tissue ([@bibr18-jabfm.5000342]). The high proliferation rate and the multipotent differentiation potential of these cells qualify them for this purpose ([@bibr19-jabfm.5000342]). However, a key role in the commitment and modulation of MSC activity towards bone regeneration is played by the presence of specific soluble mediators in the bone microenvironment. These are growth factors and cytokines, or insoluble extracellular matrix proteins, acting as paracrine regulators of stem-cell function, whose supplementation is mandatory in in vitro cultures (osteogenic media) ([@bibr20-jabfm.5000342]-[@bibr21-jabfm.5000342]-[@bibr22-jabfm.5000342]).

Among biophysical stimuli, mechanical stimuli such as high- or low-intensity ultrasounds (HIFU or LIPUS) and pulsed electromagnetic fields (PEMF) were widely investigated in their ability to induce osteogenic differentiation ([@bibr23-jabfm.5000342]-[@bibr24-jabfm.5000342]-[@bibr25-jabfm.5000342]-[@bibr26-jabfm.5000342]-[@bibr27-jabfm.5000342]-[@bibr28-jabfm.5000342]-[@bibr29-jabfm.5000342]-[@bibr30-jabfm.5000342]). Most of these stimuli act on cell structures through a mechano-transduction mechanism, converting the stimulus into chemical signals. Both types of biophysical stimuli act *in primis* at cell membrane level, which represents the system able to translate an external signal into intracellular changes by activating several signal transduction pathways. In particular, PEMF induces an increase of intracellular Ca^2+^ from the endoplasmic reticulum with consequent increase in calmodulin, a protein known for stimulating nucleotides synthesis, cell proliferation and for inducing the production of growth factors ([@bibr11-jabfm.5000342]). Changes in intracellular calcium, following the activation of ions channels are considered among the first cellular responses to mechanical stimuli ([@bibr12-jabfm.5000342]). Conversely, it is not know which mechanosensitive membrane molecules such as ionic channels, G proteins coupled receptors, adhesion molecules and cytoskeleton components, are specifically activated by LIPUS ([@bibr11-jabfm.5000342], [@bibr31-jabfm.5000342]).

LIPUS has proven to be a clinically established, widely used and FDA approved therapy to enhance bone growth during healing of non-union fractures and other osseous defects ([@bibr32-jabfm.5000342], [@bibr33-jabfm.5000342]). Various studies have also shown that ultrasound can control the rate of scaffold degradation ([@bibr13-jabfm.5000342], [@bibr34-jabfm.5000342]-[@bibr35-jabfm.5000342]-[@bibr36-jabfm.5000342]), improve scaffold integration, and that they modulate different specific cellular aspects ([@bibr14-jabfm.5000342], [@bibr29-jabfm.5000342], [@bibr37-jabfm.5000342]-[@bibr38-jabfm.5000342]-[@bibr39-jabfm.5000342]-[@bibr40-jabfm.5000342]-[@bibr41-jabfm.5000342]-[@bibr42-jabfm.5000342]). Recently, our group demonstrated that LIPUS with spatial averaged and temporal averaged (SATA) intensity of 30 mW/cm^2^ is able (i) to maintain hMSCs stemness *in vitro* for up to 28 days and therefore guarantee the presence of a stem cells reservoir and (ii) to enhance and accelerate the osteogenic differentiation of hMSCs, thereby inducing the release of a master regulator of the angiogenic process (VEGF) (unpublished data).

Starting from the hypothesis that combined differentiating stimuli might accelerate the osteogenic differentiation of hMSCs, the aim of this study was to investigate the possible adjuvant effect of LIPUS stimulation on hMSCs seeded on an innovative biomimetic composite scaffold for bone regeneration, prepared with type I collagen and co-precipitated with bioactive magnesium-doped hydroxyapatite (Mg/HA) crystals ([@bibr4-jabfm.5000342], [@bibr43-jabfm.5000342]). The attention was focused on hMSCs osteogenic differentiating capability and colonization, through the analysis of osteogenic pathways, MAPK1/6 signaling related to cell stretch and compression, and IL-8 and *VEGF* expression in response to LIPUS stimulation.

Materials and Methods {#section2-jabfm.5000342}
=====================

MgHA/Coll hybrid composite scaffold {#section2a-jabfm.5000342}
-----------------------------------

The scaffold (∅ = 6 mm, h = 5 mm) was manufactured by Fin-Ceramica Faenza SpA (Faenza -- Ravenna, Italy). A 0.04 M H~3~PO~4~ solution was mixed with the aqueous acetic buffer solution of type I atelocollagen (1 wt%), which was then dropped into a basic suspension containing Ca(OH)~2~ 0.04 M, MgCl~2~ 6H~2~O (2 × 10^−3^ M) and simulated body fluid (SBF), yielding to a magnesium-HA/collagen material with a theoretical ratio of 70/30% and Mg/Ca molar ratio of 5% in the crystal lattice ([@bibr44-jabfm.5000342]-[@bibr45-jabfm.5000342]-[@bibr46-jabfm.5000342]). Precipitate fibers were maturated for 1 hour, then washed with highly purified water and immediately submitted to a treatment of cross-linking by 48 hours' immersion in NaHCO~3~/Na~2~CO~3~ buffer solution at pH = 9.5 of 1 wt% 1, 4-butanediol diglycidyl ether (BDDGE) cross-linking agent at 37°C ([@bibr44-jabfm.5000342]). After the cross-linking reaction, the manufactured scaffold underwent a freeze-drying treatment consisting into a controlled freezing/heating ramp (from 25°C to 35°C, from 35°C to 20°C) carried out over 25 hours under vacuum conditions (0.29 mbar), to consolidate the 3D scaffold (MgHA/Coll hybrid composite) ([@bibr46-jabfm.5000342]). Finally, MgHA/Coll hybrid composite scaffolds were packed separately and sterilized with γ radiation at 25 kGy.

Ethics statement {#section2b-jabfm.5000342}
----------------

In this study, we used human mesenchymal stem cells (hMSCs, Lonza, Walkersville, MD USA) according to Lonza limited use license. Specifically, hMSCs were not used: a) in humans; b) in conjunction with human clinical trials; or c) in association with human diagnostics.

Cell culture {#section2c-jabfm.5000342}
------------

Human MSCs were cultured in mesenchymal stem cell growth medium (MSCGM™ Bullet Kit, Lonza, Walkersville, MD USA) to expand cells without inducing differentiation. The culture medium was changed every 3 days, and cells were split at 80%-90% of confluence using StemPro Accutase (Gibco by Life Technologies, Grand Islands, NY USA). To perform osteogenic differentiation, hMSCs were treated with hMSC mesenchymal stem cell osteogenic differentiation medium (OM) (hMSC Osteogenic Differentiation Bullet Kit™, Lonza).

Before cell seeding, MgHA/Coll hybrid composite scaffolds were pre-wetted in OM for 40 minutes to promote cell adhesion, hMSCs were then gently seeded onto them (25.000 cells/scaffold in 5 µL) carefully repeating cells deposition and recovery (cell engineered scaffold). This procedure let cell infiltrate into the porous structure, preventing cell dispersion. After 1 hour, each MgHA/Coll hybrid composite scaffold was carefully placed into a new 12-well plate (Costar, NY, USA) and covered with OM.

LIPUS treatment {#section2d-jabfm.5000342}
---------------

The LIPUS exposure device manufactured by IGEA SpA (Carpi-Modena, Italy) consists of an array of 5 transducers (∅ 25 mm), which are specifically designed for use in a multiwell culture plate. LIPUS signal consisted of 200 μs burst of 1.5 MHz sine waves repeating at 1 kHz and delivering 30 mW/cm^2^ SATA intensity. A calibrated force balance measured the power of the collimated ultrasound beam emitted from the transducer, which was inserted in water perpendicularly to the measuring cone and in a concentric position relative to the latter (Ultrasound Power Meters UPM-DT-1AV, Ohmic Instruments, St. Charles -- MI, US). By considering a probe value of effective radiating area of about 5.1 cm^2^, the mediated power was 33.7 mW/cm^2^. The wave form and frequency were measured using an oscilloscope (720A, Tektronix Inc., Beaverton - OR, US).

Twenty-four hours before LIPUS treatment, hMSCs cells were seeded onto the osteogenic scaffolds as described above. Cell cultures were divided in two groups for each experimental time (7 and 14 days): LIPUS-treated cultures (LIPUS scaffold) and untreated cultures (Untreated Scaffold). The culture plates were then placed on the ultrasound transducer array with a thin layer of standard ultrasound gel and exposed to LIPUS for 20 min/day for 5 consecutive days/week. The Untreated Scaffold group was handled in the same way, but the ultrasound generator was switched off. At the end of LIPUS stimulation time (14 days on), a culture plate for each group was maintained for further 7 days in the incubator at the same conditions, but without being exposed to the LIPUS device (indicated as '14 days on +7 days off'). In addition, osteogenic scaffolds without cells were cultured at the same conditions and used as negative controls.

dsDNA concentration (PicoGreen assay) {#section2e-jabfm.5000342}
-------------------------------------

The concentration of dsDNA content was quantified by using fluorimetric Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen™, Life Technologies - EuroClone S.p.A, Pero-Milan, Italy). After scaffold washing with phosphate-buffered saline, 250 μL of lysis solution were added to each MgHA/Coll hybrid composite scaffold and cell lysis was then completed by 3 freeze-thaw cycles. After 5 minutes of incubation at room temperature (RT) and protected from light, dsDNA content was calculated from the lysates adding 100 μL of fluorescent nucleic acid stain to each scaffold ([@bibr47-jabfm.5000342]). Fluorescence was measured using a GloMax multiwell plate reader (GloMax, Promega Corporation Madison, WI).

Scanning electron microscopy (SEM) {#section2f-jabfm.5000342}
----------------------------------

Both LIPUS Scaffolds and Untreated Scaffolds were fixed for 20 minutes in 2.5% glutaraldehyde in 0.1 saline buffer at pH 7.2, at RT to provide a rapid inter- and intra-cellular penetration and fixation, followed by post-fixation in saline buffer, with 3 changes for 10 minutes at RT. The fixed scaffolds were taken through a series of increasing concentrations of a drying ethanol solution (10%, 20%, 30%, 50%, 70%, 90%) ending in a 100% dehydrating liquid of the highest possible purity. After having carried out a critical point drier (K850 Critical Point Drier, Quorum Technologies LTD, Ashford UK -- Assing SpA, Monterotondo-Roma, Italy), scaffolds were gold coated (B7340 Manual Sputter Coater Assing SpA) and then analyzed using a scanning electron microscope (EVO LS - ZEISS, Assing SpA). The backscattered electron observations were performed at 20 kV.

Reverse transcriptase - quantitative polymerase chain reaction (RT-qPCR) analysis {#section2g-jabfm.5000342}
---------------------------------------------------------------------------------

Total RNA was extracted from the scaffold using Trizol reagent (Invitrogen™). Each cDNA sample was tested in duplicate. Quantitative RT-PCR analysis was performed in a LightCycler 2.0 Instrument (Roche Diagnostics SpA, Milan, Italy) using SYBR® Green Real-Time PCR Master Mixes (Applied Biosystems™, Life Technologies - EuroClone S.p.A). QuantiTect Primers (Qiagen Srl, Milan, Italy) and designed primers (Invitrogen™) were used ([Tab. I](#table1-jabfm.5000342){ref-type="table"}). Gene expression analysis was performed employing the 2^−ΔΔCT^ method using *GAPDH* expression as reference gene ([@bibr48-jabfm.5000342]). Results were expressed as relative fold changes calculated using Untreated Scaffold data as calibrator for each experimental time point.

###### 

Gene primers specific for osteogenic differentiation or involved in the differentiating process. Expression was normalized versus GAPDH reference gene

![](10.5301_jabfm.5000342-table1)

  Gene       Forward primer          Reverse primer            Annealing temperature (°C)
  ---------- ----------------------- ------------------------- ----------------------------
  *RUNX2*    Hs_RUNX_l\_SG                                     60
  *ALPL*     Hs_ALP_1\_SG                                      60
  *COL1A1*   Hs_COL1A1_l\_SG                                   60
  *BGLAP*    Hs_BGLAP_1\_SG                                    60
  *SPP1*     Hs_SPP1_1\_SG                                     60
  *MAPK1*    GCGCTACACTAATCTCTCGT    CTGAGGTGCTGTGTCTTCAA      60
  *MAPK6*    GAATGGCAAATCTGCTCAATT   ACAGTCCTCCCCACCACTCA      60
  *VEGF*     Hs_VEGFB_1\_SG                                    60
  *GAPDH*    ATGGGGAAGGTGAAGGTCG     GGGTCATTGATGGCAACAATATC   65

ELISA assays {#section2h-jabfm.5000342}
------------

Protein release in the culture medium for alkaline phosphatase (ALP), collagen type I alpha 1 (COL1a1), osteopontin (OPN), and the cellular content of osteocalcin (OC) were evaluated by Cloud-Clone ELISA kit (Cloud-Clone Corp. Houston, TX, USA), while interleukin 8 (IL8) (human IL8 ELISA KIT KHC0081) was evaluated by Invitrogen ELISA KIT assay (Invitrogen, Thermo Scientific, Italy). Values were normalized for medium protein content evaluated by Bradford assay.

Statistical Analysis {#section2i-jabfm.5000342}
--------------------

The results of each performed analysis was obtained by three independent experiments in replication. Statistical analysis was performed using the IBM® SPSS® Statistics 23 software. Results of LIPUS Scaffold group were expressed as mean ± standard deviation (SD) of increase (fold of increase - FOI) compared to Untreated Scaffold group at each experimental time and at a significance level of p\<0.05.

After having verified the normal distribution (Kolmogorov-Smirnov test) and homoscedasticity (Levene test) of the data, one-way ANOVA, followed by adjusted Sidak\'s multiple comparison test, was performed to assess the influence of LIPUS treatment exposure on hMSCs osteogenic differentiation.

Results {#section3-jabfm.5000342}
=======

Mg-HA/collagen porous composite scaffold {#section3a-jabfm.5000342}
----------------------------------------

Physical-chemical characterization results of MgHA/Coll hybrid scaffold have been previously reported ([@bibr44-jabfm.5000342]-[@bibr45-jabfm.5000342]-[@bibr46-jabfm.5000342]). SEM analysis showed that the Mg-HA/collagen porous composite scaffold presented a homogenous structure with tridimensional high porosity (83.8 ± 5.3%), a high degree of pore interconnectivity (mean size \>100 µm) and evident large channel around 600 micron ([@bibr44-jabfm.5000342]-[@bibr45-jabfm.5000342]-[@bibr46-jabfm.5000342]). EDS semiquantitative analysis of the elements contained in the MgHA/Coll hybrid composite scaffold showed a 0.32 ± 0.04 wt% for Mg, 20.31 ± 0.18 wt% for Ca and 10.08 ± 0.13 wt% for P ([@bibr46-jabfm.5000342]). The mineral content analyses of this scaffold showed a strong interaction between the organic and inorganic (Mg-HA 50.5 ± 1.0 wt%) components, with the mineral phase structurally confined by the organic template and collagen enzymatic degradation completed in more than 5 months ([@bibr44-jabfm.5000342], [@bibr45-jabfm.5000342]). Transmission electron microscopy highlighted the enucleation of HA on collagen of Mg-HA/collagen porous composite scaffold and the presence of HA crystals inside the collagen matrix ([@bibr46-jabfm.5000342]). Finally, inductively coupled plasma-optical emission spectrometry highlighted that 40 ± 1 w/w% Mg ions were released within one day and no significant differences in Mg ions release were found over 14 days ([@bibr46-jabfm.5000342]).

Cell viability {#section3b-jabfm.5000342}
--------------

To evaluate hMSCs viability and amount on MgHA/Coll hybrid composite scaffold, the PicoGreen® dsDNA quantification assay was used ([Fig. 1](#fig1-jabfm.5000342){ref-type="fig"}). The LIPUS treatment did not alter dsDNA content on engineered osteogenic scaffolds and, after the end of treatment (14 days on +7 days off), an increase in dsDNA content (1.7 FOI) was found in the LIPUS Scaffold group compared to the Untreated Scaffold group (F = 53.66, p\<0.0005, *f* = 0.55).

![Amount of cells. DNA quantification of hMSCs seeded onto osteogenic scaffold and treated with LIPUS stimulation (LIPUS Scaffold) at each experimental time point, expressed as fold of increase (FOI) of Untreated Scaffold data (FOI = 1). Data are reported as mean±SD (n = 3, replicates). Adjusted Sidak\'s multiple comparison test:](10.5301_jabfm.5000342-fig1){#fig1-jabfm.5000342}

Ultrastructural analysis {#section3c-jabfm.5000342}
------------------------

SEM analysis showed the capability of hMSCs to colonize the MgHA/Coll hybrid composite scaffold ([Fig. 2](#fig2-jabfm.5000342){ref-type="fig"}). Untreated Scaffolds showed the same hMSCs colonization at every time point ([Figs. 2A](#fig2-jabfm.5000342){ref-type="fig"}, [2C](#fig2-jabfm.5000342){ref-type="fig"}, [2E](#fig2-jabfm.5000342){ref-type="fig"}), confirming the data obtained by hMSCs viability analysis. Conversely, an increase of hMSCs colonization in LIPUS Scaffold group was more evident after 14 days of LIPUS treatment, remaining constant even after the LIPUS treatment was switched off ([Figs. 2B](#fig2-jabfm.5000342){ref-type="fig"}, [2D](#fig2-jabfm.5000342){ref-type="fig"}, [2F](#fig2-jabfm.5000342){ref-type="fig"}).

![Ultrastructural analysis. SEM images of untreated (Untreated Scaffold: A, C and E) and LIPUS treated (LIPUS scaffold: B, D and F) engineered osteogenic scaffold at 7d (**A** and **B**), 14d (**C** and **D**), and 14 days on +7 days off (**E** and **F**) (scale bar: 10 µm). The arrows indicate hMSCs spreading onto the scaffold surface.](10.5301_jabfm.5000342-fig2){#fig2-jabfm.5000342}

Gene expression {#section3d-jabfm.5000342}
---------------

LIPUS treatment induced a gene expression modulation of several genes involved both in osteoblast differentiation (*ALPL*, *COL1A1*, *BGLAP* and *SPP1*), MAPK/ERK pathway (*MAPK1* and *MAPK6*) and angiogenesis pathways (*VEGF*) ([Fig. 3](#fig3-jabfm.5000342){ref-type="fig"}). In particular, LIPUS treatment produced: (i) no significant *RUNX2* gene expression modulation; (ii) a constant increase of *ALPL* gene expression after 14 days of treatment (11.8 FOI), which grew further at 14 days on +7 days off (22.0 FOI) compared to the Untreated Scaffold group (F = 29.77, p\<0.005, *f* = 0.58) and no modulation of *COL1A1* compared to the Untreated Scaffold group ([Fig. 3A](#fig3-jabfm.5000342){ref-type="fig"}); (iii) an increase of *BGLAP* (F = 65.65, p\<0.0005, *f* = 0.57) gene expression at 14 days (1.58 FOI) ([Fig. 3B](#fig3-jabfm.5000342){ref-type="fig"}); (iv) an increase of *MAPK1* and *MAPK6* expression compared to the Untreated Scaffold group: in detail, *MAPK1* increased after 7 days of treatment (5.6 FOI) and remained constant over time (F = 0.22, NS), while *MAPK6* increased at 14 days (4.9 FOI, F = 6.55, p\<0.05, *f* = 0.52) ([Fig. 3C](#fig3-jabfm.5000342){ref-type="fig"}); and finally (v) an increase in *VEGF* (F = 6.01, p\<0.05, *f* = 0.54) expression in comparison with the Untreated Scaffold group, at 14 days (5.0 FOI), which remained constant up to 14 days on +7 days off of LIPUS treatment ([Fig. 3C](#fig3-jabfm.5000342){ref-type="fig"}).

![Gene expression analysis. Relative gene expression of osteoblast markers (*RUNX2*, *ALPL* and *COL1A1*), osteoblast target genes (*BGLAP* and *SPP1*) and cell cycle genes (*MAPK1*, *MAPK6* and *VEGF*) in hMSCs seeded onto osteogenic scaffold and treated with LIPUS stimulation (LIPUS Scaffold) at each experimental time point, expressed as fold of increase (FOI) of Untreated Scaffold data (FOI = 1, dot line). Data are reported as mean ± SD (n = 3, replicates). Adjusted Sidak\'s multiple comparison test:](10.5301_jabfm.5000342-fig3){#fig3-jabfm.5000342}

Protein release {#section3e-jabfm.5000342}
---------------

LIPUS stimuli did not induce an ALP release, and values stayed below those of the Untreated Scaffold group ([Fig. 4](#fig4-jabfm.5000342){ref-type="fig"}). COL1a1 release was significantly higher at 7 days, decreasing below the values of the Untreated Scaffold group over time (F = 6.01, p\<0.05, *f* = 0.54). OCN and OPN protein release showed an increase in comparison to the Untreated Scaffold group (OCN: FOI \>5 and OPN: FOI \>3), which remained constant over time ([Fig. 4](#fig4-jabfm.5000342){ref-type="fig"}). LIPUS treatment caused an increase in IL8 release (3.5 FOI) at 7 days of treatment and at 14 days on +7 days off (F: 14.98, p\<0.005, *f* = 0.88).

![Protein release. ALP, COL1a1, OCN, OPN, and IL8 release by hMSCs seeded onto osteogenic scaffold and treated with LIPUS stimulation (LIPUS scaffold) at each experimental time point, expressed as fold of increase (FOI) of untreated scaffold data (FOI = 1, dot line). Data are reported as mean ± SD (n = 3, replicates). Adjusted Sidak\'s multiple comparison test:](10.5301_jabfm.5000342-fig4){#fig4-jabfm.5000342}

Discussion {#section4-jabfm.5000342}
==========

The physical and chemical characteristics of a scaffold, as well as its osteointegration capability, have a fundamental role in the initial stage of bone regeneration. Nevertheless, it is necessary to guarantee hMSCs colonization into the scaffold, to commit hMSCs towards the osteoblastic lineage and to increase scaffold osteointegration capability through various strategies, including biophysical stimuli. The present study was carried out by using an innovative osteogenic scaffold -- MgHA/Coll hybrid composite, whose physical and chemical characteristics, as well as its biocompatibility, had already been investigated ([@bibr44-jabfm.5000342], [@bibr46-jabfm.5000342]). Its fiber orientation, pore size and interconnectivity, together with the wettability of scaffold surfaces, could regulate cellular attachment and infiltration of the matrix, tuning the regeneration process. Natural polymers, such as collagen, are mechanically weaker, but flexible and usually contain specific molecular domains that induce and support cell bioactivity and biofunctionality.

Recent studies demonstrated that LIPUS stimuli transmit signals into the cell via an integrin that acts as a mechanoreceptor on the cell membrane ([@bibr49-jabfm.5000342]). Other studies have proven that LIPUS treatment exerts a direct anabolic effect in osteoblasts, stimulating growth factors release, ALP activity, osteogenic differentiation, extracellular matrix production and accelerating calcium deposition ([@bibr50-jabfm.5000342]). For these reasons, osteogenic-specific pathways modulation (*ALP*, *COL1A1, RUNX2*, *BGLAP, SPP1*), cell cycle (*MAPK1* and *MAPK6*), angiogenetic (IL8 and *VEGF*) and inflammatory (IL6) specific factors were currently investigated.

The present results showed that LIPUS stimulation of hMSCs engineered scaffold can increase cell proliferation and MgHA/Coll hybrid composite scaffold colonization, in particular at 14 days on +7 days off of stimuli. This is probably due to the *MAPK* pathway activation, as highlighted by *MAPK6* gene expression increase at 14 days and 14 days on +7 days off. *MAPKs* are serine/threonine kinases that regulate important cellular processes, including gene expression and cell proliferation, survival, death and motility ([@bibr51-jabfm.5000342]). The role of *MAPKs/ERKs* in early stage differentiation of osteoblasts is currently debated, but many reports suggested that MAPKs activation is necessary for the maturation and mineralization of osteoblasts by inducing osteocalcin production ([@bibr52-jabfm.5000342], [@bibr53-jabfm.5000342]). Some studies support a stimulatory role in osteoblast differentiation, while others suggest that this pathway has an inhibitory role instead ([@bibr54-jabfm.5000342]). The observed positive regulation of osteoblast late markers, such as OPN and OCN release in a time-dependent manner, suggested that LIPUS stimuli and MgHA/Coll hybrid composite scaffold might have a synergic role on hMSCs osteogenic differentiation, probably through *MAPK* pathway ([@bibr52-jabfm.5000342], [@bibr53-jabfm.5000342]). On the contrary, the absence of the early ALP marker modulation after LIPUS treatment did not highlight the same synergic role, suggesting the importance of MgHA/Coll hybrid composite scaffold in the early step of the differentiation process, whereas LIPUS treatment seems to act on the late differentiation step. BGLAP, showed only a little and biologically insignificant decrease of RNA expression, probably due to high levels of protein.

Data on *VEGF* gene expression demonstrated that there was an increase of *VEGF* gene expression in LIPUS Scaffold group after 14 days of stimulation, which remained after 7 days without treatment. MAPK pathway activation seems to be determined by mechanical stress on the cellular plasma membrane and cytoskeletal structures. Similarly, the biophysical effects of LIPUS induced intracellular signal transductions and gene transcriptions ([@bibr55-jabfm.5000342]), leading to *VEGF* gene over expression ([@bibr56-jabfm.5000342]). *VEGF* is highly expressed in osteoblastic precursor cells and known to stimulate bone formation. In the present study, LIPUS treatment caused an increase in IL8 release. It was reported that, during the osteogenic differentiation process, hMSCs are able to release IL8 to support development, differentiation and regeneration processes. IL8 signaling is also a mediator of the angiogenesis pathway in synergy with VEGF-a ([@bibr55-jabfm.5000342], [@bibr57-jabfm.5000342]-[@bibr58-jabfm.5000342]-[@bibr59-jabfm.5000342]). On the other hand, the maintenance of basal expression levels of IL6 by LIPUS treatment might suggest a decrease in bone resorption ([@bibr60-jabfm.5000342]), whereas the up-regulation of IL8 might suggest the hypothetical activation of angiogenesis pathway after osteogenic differentiation stimuli (14 days on +7 days off) useful for bone engineering approach. For these reasons, the current IL8 and VEGF results support the hypothesis that LIPUS is able to stimulate angiogenesis.

In conclusion, the current study showed that the mechanical stimuli by LIPUS treatment improved colonization and differentiation of hMSCs seeded on a new biomimetic scaffold for bone regeneration. Based on these results, we think that LIPUS treatment might be applied to improve scaffold colonization and osteointegration acting as an adjuvant therapeutic approach useful to accelerate bone regeneration pathways.
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